Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Dong-A
Company Location: Asia Pacific
Company Founding Year: 1932
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Gastritis, Atrophic|Keratoconjunctivitis Sicca|Dry Eye Syndromes
Phase 2: Dry Eye Syndromes|Keratoconjunctivitis Sicca
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01162954 |
DA6034_DES_I | P1 |
Completed |
Dry Eye Syndromes|Keratoconjunctivitis Sicca |
2009-03-01 |
2019-03-19 |
Treatments |
|
NCT06337981 |
21DE20901 | P2 |
Completed |
Dry Eye Syndromes|Keratoconjunctivitis Sicca |
2022-06-14 |
2024-04-05 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT01670357 |
DES | P2 |
Completed |
Dry Eye Syndromes|Keratoconjunctivitis Sicca |
2013-03-01 |
2019-03-19 |
Treatments |
|
NCT06291194 |
22DE30902 | P3 |
Unknown status |
Dry Eye Syndromes|Keratoconjunctivitis Sicca |
2024-05-01 |
37% |
2026-05-01 |
Primary Endpoints|Treatments|Trial Status |
NCT01813812 |
DA6034_Gas_III (Version 4.3) | P3 |
Unknown status |
Gastritis, Atrophic |
2013-08-01 |
2019-03-19 |
Recent News Events
Date |
Type |
Title |
|---|